Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy

Michele Cavo • 28 Sep 2023
IMS 2023
Multiple Myeloma Antibodies CAR-T

Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the value of immunotherapeutic agents, including CAR-T cells and bispecific antibodies, in the treatment of patients with triple-class refractory multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michele Cavo

1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022
3:14
The prognostic value of MRD negativity
Michele Cavo • 17 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals